Author Archives: Alina Peon

Dalton Chief Investment Officer Interviewed by Nikkei Business on Why Poison Pills Do Not Work

Dalton CIO, James B. Rosenwald III, recently interviewed with Nikkei Business, discussing recent announcements by Aska Pharmaceutical and Bunka Shutter to potentially implement a poison pill in order to block shareholder efforts to have each company consider going private.  The …
read more >

Posted in Dalton in the News | Comments Off on Dalton Chief Investment Officer Interviewed by Nikkei Business on Why Poison Pills Do Not Work

Dalton Responds to Aska’s Threat of a Poison Pill

On September 30th, 2025, Dalton Investments (“Dalton”) sent a letter to Aska Pharmaceutical addressing its objections to considering a management buyout and the threat that it would enact a poison pill if Dalton increased its ownership level to 30%.  Excerpts …
read more >

Posted in Dalton Actions | Comments Off on Dalton Responds to Aska’s Threat of a Poison Pill

Dalton Investments Highlighted in “Diligent Market Intelligence: Shareholder Activism in Asia 2025 Report”

In their report “Diligent Market Intelligence: Shareholder Activism in Asia 2025”, Diligent highlights Dalton as one of “Asia’s top activist investors”. When the activity of Dalton Investments and its affiliate company Rising Sun Management (through the closed end fund Nippon …
read more >

Posted in Dalton in the News | Comments Off on Dalton Investments Highlighted in “Diligent Market Intelligence: Shareholder Activism in Asia 2025 Report”

Dalton Sends Letter to Aska Pharmaceuticals Holdings and Bunka Shutter Criticizing their Potential Use of Poison Pills

Dalton Investments, a major shareholder of Aska Pharmaceuticals and Bunka Shutter, has sent a letter to both companies criticizing their adoption of a “Response Policy on Large-Scale Purchase of Shares”. The letter outlines four key points of Dalton’s position. Read …
read more >

Posted in Dalton Actions | Comments Off on Dalton Sends Letter to Aska Pharmaceuticals Holdings and Bunka Shutter Criticizing their Potential Use of Poison Pills

Dalton Blasts Japan’s Aska Pharma, Bunka Shutter for Takeover Defenses

Dalton Investments’ response to the anti-takeover measures adopted by Aska Pharma and Bunka Shutter—two companies in which it is a major shareholder—was recently featured in Nikkei Asia. Read the article here. 

Posted in Dalton in the News | Comments Off on Dalton Blasts Japan’s Aska Pharma, Bunka Shutter for Takeover Defenses

Japan’s Upper House Election Update

Shiro Hayashi, Director of Research and Head of Dalton’s Tokyo research office, discusses the recent House of Councillors (Upper House) election in Japan, where the Liberal Democratic Party (LDP) and its coalition partner Komeito suffered a second consecutive defeat. Read …
read more >

Posted in Dalton Insights | Comments Off on Japan’s Upper House Election Update

Implementation of Fuji Media Holdings’ Reform Action Plan and Introduction of Takeover Defense Measures Against the Murakami Fund

Rising Sun Management, an affiliate of Dalton, has sent a letter to Fuji Media Holdings regarding the implementation of a reform action plan and the introduction of takeover defense measures against the Murakami Fund. Read the letter here. This document …
read more >

Posted in Dalton Actions | Comments Off on Implementation of Fuji Media Holdings’ Reform Action Plan and Introduction of Takeover Defense Measures Against the Murakami Fund

Request for Consideration of Timing of AGMs & Early Reporting

Dalton Investments has sent a letter to the boards of directors of its portfolio companies, requesting consideration of early disclosure of securities reports and the “de-concentration” of annual general meetings dates. We have long held the view that the information …
read more >

Posted in Dalton Actions | Comments Off on Request for Consideration of Timing of AGMs & Early Reporting

A Response to ASKA’s New Policy for “Large Scale Purchase Actions”

Dalton Investments’ affiliate, Rising Sun Management Ltd. (“RSM”), has sent a letter to the Board of Directors of ASKA Pharmaceutical Holdings Co., LTD (“ASKA”) to share its concerns about the company’s recently-adopted “Policy for Responding to Large-Scale Purchase Actions” and …
read more >

Posted in Dalton Actions | Comments Off on A Response to ASKA’s New Policy for “Large Scale Purchase Actions”

Dalton CIO Jamie Rosenwald appears on Investor’s Sunday Podcast

Dalton CIO Jamie Rosenwald recently appeared on Investor’s Sunday, which is a regular show on Tokyo’s InterFM. The show is co-hosted by Yuko Ezure and Dalton’s own Masumi Nishida, Partner and Managing Director for Dalton’s Tokyo research office. The show …
read more >

Posted in Dalton in the News | Comments Off on Dalton CIO Jamie Rosenwald appears on Investor’s Sunday Podcast